imiquimod has been researched along with ribavirin in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 2 (50.00) | 24.3611 |
2020's | 1 (25.00) | 2.80 |
Authors | Studies |
---|---|
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
Blatt, LM; Day, CW; Julander, JG; Morrey, JD; Sidwell, RW; Smee, DF | 1 |
Aoki, Y; Hiramine, S; Imamura, M; Ito, K; Kanto, T; Kimura, T; Kirikae, I; Korenaga, M; Masaki, N; Matsui, T; Mizokami, M; Murata, K; Saito, H; Sugiyama, M; Yoshio, S | 1 |
4 other study(ies) available for imiquimod and ribavirin
Article | Year |
---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Effect of interferon-alpha and interferon-inducers on West Nile virus in mouse and hamster animal models.
Topics: Aminoquinolines; Animals; Cells, Cultured; Cricetinae; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Imiquimod; Interferon Inducers; Interferon Type I; Interferon-alpha; Interferons; Mice; Mice, Inbred BALB C; Motor Activity; Poly I-C; Poly U; Recombinant Proteins; Ribavirin; Survival Rate; Time Factors; West Nile Fever; West Nile virus | 2004 |
Ex vivo induction of IFN-λ3 by a TLR7 agonist determines response to Peg-IFN/ribavirin therapy in chronic hepatitis C patients.
Topics: Aged; Aminoquinolines; Antiviral Agents; Cells, Cultured; Dendritic Cells; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Imiquimod; Interferon-alpha; Interferons; Interleukins; Leukocytes, Mononuclear; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Ribavirin; RNA, Messenger; Toll-Like Receptor 7; Treatment Outcome | 2014 |